Mark Udall actually said...

"I do understand, Mr. Blum, that if the IPAB recommendations are not acceptable to the Congress, we can simply override them with our own ideas and our own proposals about how to contain costs."

"Again, the point of the hearing is how do we maintain quality, how do we encourage the pharmaceutical sector to innovate and take some risks, but how do we get a handle on the enormous cost of providi..."

"And that's the point of the hearing today, and I want to thank Senator Kohl and Senator Corker for convening this."

"I'm highly worried that before the legislation we didn't even have an IPAB. Now we have an IPAB, and I think its goal inevitably will be to metastasize into what the British have."